AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data

Kalaris Therapeutics, Inc.

2023-Q3 EPS reported -$1.30

Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.
Cash, equivalents and short-term investments $213.3M at Sep 30, down from $233.8M at Dec 31, 2022.
R&D expense $34.2M, up from $30.0M YoY, driven by posoleucel trial costs.
Three Phase 3 posoleucel trials enrolling; topline data expected in H2 2024 for all three.
FY 2023 operating expense guidance $150M-$170M, excluding non-cash items.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Kalaris Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income net loss was $44.3 million or $0.39 per share, EPS $0.39 per share.

Period: the quarter ended September 30, 2023
Net income: net loss was $44.3 million or $0.39 per share
EPS: $0.39 per share
Result: reported results

Exact text from the filing

On November 2, 2023, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-268875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.